Xenon Pharmaceuticals Inc. 8-K

What Happened
Xenon Pharmaceuticals Inc. (XENE) announced its financial results for the year ended December 31, 2025 via a press release dated February 26, 2026, and furnished that release to the SEC as Exhibit 99.1 in an 8-K filing. The report was signed on behalf of the company by Thomas P. Kelly, Chief Financial Officer. The 8-K indicates the press release contains the detailed results (revenue, earnings, cash position, and related metrics).

Key Details

• Press release reporting Xenon’s full-year 2025 financial results furnished to the SEC on February 26, 2026 (Exhibit 99.1).
• Results cover the fiscal year ended December 31, 2025.
• Company states it announces material information through SEC filings, press releases, investor web pages and social media (X @XenonPharma, LinkedIn, Facebook).
• Filing was furnished (provided to the SEC) rather than filed; signed by CFO Thomas P. Kelly.

Why It Matters
This 8-K signals that Xenon has publicly released its 2025 financial performance; those numbers can affect investor views of revenue, profitability, cash runway and near-term strategy. Retail investors should read the attached press release and check Xenon’s investor site or company announcements for the full financial details, guidance (if any), and any management commentary. Because Xenon uses multiple public channels to disclose material information, follow the company’s investor relations pages or social accounts for timely updates.